Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs

INTRODUCTION: Assess the cost-effectiveness (US healthcare payer perspective) of sarilumab subcutaneous (SC) 200 mg + methotrexate versus conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) or targeted DMARD + methotrexate for moderate-to-severe rheumatoid arthritis (RA) in adul...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Adv Ther
Main Authors: Muszbek, Noemi, Proudfoot, Clare, Fournier, Marie, Chen, Chieh-I, Kuznik, Andreas, Kiss, Zsofia, Gal, Peter, Michaud, Kaleb
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Healthcare 2019
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6824456/
https://ncbi.nlm.nih.gov/pubmed/31004324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-019-00946-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados